Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 549 participants.

Also called NCT05462145

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 549 participants (planned count) (from the registry)
Sponsor
  • Kardium Inc. Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05462145
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Canada, Czechia, Germany (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT05462145. Allocation not applicable; no masking; primary purpose treatment. Start 2023-03-09 (actual); primary completion 2029-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation
Acronym
PULSAR
Condition
Paroxysmal Atrial Fibrillation
Condition
Persistent Atrial Fibrillation
Intervention (Device)
Globe Pulsed Field System
Lead sponsor
Kardium Inc. (class: industry)

Record details

Record id
cardio:ct-nct05462145
Content hash
a28cb3e6abe93e77984de05724e4a8ef9cff3ff1e88ebe6160945e597681e8ae